Introduction {#s1}
============

Road tunnels are increasingly being constructed in major world cities to help alleviate traffic congestion. They are often located within densely populated areas, have high traffic volumes, including a substantial proportion of heavy duty vehicles, and pollutants are commonly vented to the external environment through stacks [@pone.0048921-Bartonova1]--[@pone.0048921-Kuykendall1]. However, studies investigating the health impact of traffic-related air pollution (TRAP) on communities residing around road tunnels, or their ventilation stacks and portals, are scarce, probably due to difficulty in disentangling health effects associated with general traffic from effects attributable to emissions arising in the tunnels [@pone.0048921-National1].

We are aware of only one study that has investigated health effects associated with exposure to road tunnel stack emissions [@pone.0048921-Capon1]. This cross-sectional study, conducted after the tunnel was opened, found no difference in the prevalence of self-reported respiratory and irritant symptoms between three zones estimated to have varying exposure to the ventilation stack plume.

The Lane Cove Tunnel (LCT) is a 3.6 km long road tunnel that connects two motorways and is vented by two stacks located near each end of the tunnel. Modelling prior to tunnel construction predicted that areas around the tunnel feeder roads would experience increased exposure to nitrogen dioxide (NO~2~) and particulate matter (PM), and areas adjacent to the bypassed main road would experience a decrease in exposure [@pone.0048921-RTA1]. Modelling of stack emissions forecast little detectable impact on the surrounding area. The tunnel commenced operation on 25 March 2007, with an average of 43,446 vehicles per day (vpd) during May, 2007 increasing to 58,218 vpd by November, 2008, with 2.9% and 3.5% of vehicles respectively classified as heavy or articulated vehicles. Opening of the tunnel was accompanied by an approximate halving of vehicle numbers from 90,000 vpd along the bypassed main road [@pone.0048921-RTA2].

![Map of study area showing the zones, tunnel, ventilation stacks and land use.](pone.0048921.g001){#pone-0048921-g001}

This study was commissioned by the NSW Health Department to inform public policy on road tunnels and their ventilation stacks and to opportunistically study respiratory health effects of a substantial traffic intervention. The principal hypothesis was that, after tunnel opening, adverse respiratory health outcomes would increase among residents near the tunnel feeder roads and decrease among residents along the bypassed main road, after adjustment for concurrent changes in a control zone. A subsidiary hypothesis was that people living around the ventilation stack would not experience a change in respiratory health status.

![Participation flowchart.\
^1^ Estimate derived from census of households within the study area. ^∧^ Eligible cohort = 2007 cohort + additional households potentially eligible to be interviewed in 2008. ^∧∧^ Subjects approached to participate in panel study. ^\*^ Subjects who took part in spirometry and eNO measurement. ^\*\*^ Subjects who took part in daily lung function and symptom diary. Blue arrow: Household and participant participation. Red arrow: Loss to follow-up.](pone.0048921.g002){#pone-0048921-g002}

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

Approval for the study was obtained from the University of Sydney Human Research Ethics Committee (HREC). Recruitment of subjects occurred through a household doorknock survey. At the time of the home visit an introductory letter about the study was provided to an adult resident, the nature of the study was discussed, and consent to participate in the survey was sought. If consent was given, this adult was considered to be the "primary respondent" for the household, and was interviewed using a standardised questionnaire. Parents completed questionnaires for children less than 16 years, and children aged 16--18 years completed questionnaires with a parent/caregiver present. Self-completion questionnaires were left for other household adults not present at the time of the visit. Up to three follow-up phone calls were made for return of the self-completed questionnaires. Interviewers returned to households up to three times and left calling cards for households unable to be contacted. The household contact and interviewing process was documented using a standardised form. Participants in the panel sub-cohort provided separate and additional written consent. The recruitment process for the whole cohort and sub-cohort was approved by the HREC.

10.1371/journal.pone.0048921.t001

###### Symptom prevalence and other characteristics of the study cohort by zone and year (n = 2978).
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                                                                 Reduced exposure zone   Increased exposure zone[a](#nt101){ref-type="table-fn"}   Eastern stack zone[a](#nt101){ref-type="table-fn"}   Control zone                                                           
  ------------------------------------------------------------- ----------------------- --------------------------------------------------------- ---------------------------------------------------- -------------- -------- -------- ----- -------- -------- ----- -------- --------
  **n**                                                                  1024                                      756                                                    608                               589         422      302     645    500      394     768    537      424
  **(% of 2006)**                                                                                                \(74\)                                                  \(59\)                                        \(72\)   \(51\)         \(78\)   \(61\)         \(70\)   \(55\)
  **%**                                                                                                                                                                                                                                                                        
  Adult (age ≥18 yrs)                                                     72                                       70                                                      68                                74          72       71     75      72       72     72      72       72
  Female                                                                  56                                       57                                                      58                                53          54       57     54      53       54     53      54       54
  Diagnosed asthma                                                        18                                       20                                                      20                                18          24       21     16      19       21     15      17       19
  Current asthma                                                          11                                       13                                                      13                                12          14       12      9      12       12      9      10       9
  Wheeze                                                                  15                                       18                                                      15                                14          19       18     11      20       17     10      13       13
  Asthma medication                                                       11                                       14                                                      15                                11          14       14     10      14       13      9      10       11
  Inhaled corticosteroids                                                  6                                        8                                                      9                                 4           8        7       4      7        6       5      5        7
  Cough                                                                   40                                       49                                                      50                                33          52       48     36      52       53     34      47       48
  Lower resp. symptoms[b](#nt102){ref-type="table-fn"}                    39                                       47                                                      47                                35          51       50     34      48       52     33      43       43
  Severe lower resp. symptoms[b](#nt102){ref-type="table-fn"}             10                                       11                                                      12                                12          14       13      8      17       12      8      9        10
  Upper resp. symptoms[b](#nt102){ref-type="table-fn"}                    17                                       24                                                      22                                10          25       28     12      27       25     12      22       20
  Mouth symptoms                                                          14                                       17                                                      18                                9           21       21     11      24       22     13      17       18
  Smoker [c](#nt103){ref-type="table-fn"}                                  7                                        6                                                      6                                 12          10       9      11      9        7      12      13       10
  ***Home environmental factors***                                                                                                                                                                                                                                             
  Unflued gas heater                                                      25                                       28                                                      33                                12          21       25     18      25       27     20      24       29
  Gas cooktop or oven                                                     52                                       58                                                      59                                25          52       51     44      56       56     42      46       48
  ETS[d](#nt104){ref-type="table-fn"} at home                              7                                        3                                                      4                                 14          9        10      8      5        5       8      5        7
  ***Educational status***                                                                                                                                                                                                                                                     
  Tertiary educated                                                       61                                       65                                                      64                                46          46       44     62      61       61     44      42       36
  High school/diploma[e](#nt105){ref-type="table-fn"}                     31                                       28                                                      28                                43          38       41     31      34       31     43      38       46
  Up to middle school[f](#nt106){ref-type="table-fn"}                      8                                        8                                                      8                                 11          16       15      7      6        7      13      19       18
  ***Work status***                                                                                                                                                                                                                                                            
  Paid Work                                                               74                                       76                                                      77                                66          70       70     75      76       78     71      70       73

Participants in overlapping area of increased exposure zone and stack zone, entire cohort (2006 = 48; 2007 = 24; 2008 = 15) contributed data to both zones.

Composite variables derived from questionnaire data (see Supporting information, [Table S1](#pone.0048921.s001){ref-type="supplementary-material"}).

Subjects \<18 years assumed to be non-smokers.

Environmental tobacco smoke.

Included Diploma/TAFE, and participants who responded "Other".

Included participants who refused to respond.

Subject Recruitment and Exposure Assignment {#s2b}
-------------------------------------------

We recruited a cohort of 2,978 participants during June-December 2006 (pre-tunnel opening) and followed them up during the same time of year in 2007 and 2008 (post-tunnel opening), within two weeks of their initial participation date. Participants were recruited by door-knocking all households within four exposure zones ([Figure 1](#pone-0048921-g001){ref-type="fig"}), defined as follows:

a.  a zone along the bypassed main road (predicted '*decreased exposure zone'*);

b.  a zone around the tunnel feeder roads (predicted *'increased exposure zone'*);

c.  a zone of 650 m radius around the tunnel's eastern ventilation stack (*'stack zone'*); and,

d.  a control zone.

10.1371/journal.pone.0048921.t002

###### Lung function measures, and other characteristics of the diary panel sub-cohort, by zone and year (n = 380)[a](#nt107){ref-type="table-fn"}.
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                                                            Reduced exposure zone   Increased exposure zone[b](#nt108){ref-type="table-fn"}   Eastern stack zone[b](#nt108){ref-type="table-fn"}   Control zone                                                                                      
  -------------------------------------------------------- ----------------------- --------------------------------------------------------- ---------------------------------------------------- -------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  **n** [c](#nt109){ref-type="table-fn"} **(% of 2006)**             93                                     85 (91)                                                79 (85)                              98         77 (78)     70 (71)       97        85 (88)     74 (76)       98        71(72)      61(62)
  **%**                                                                                                                                                                                                                                                                                              
  Adult                                                              46                                       42                                                      41                                48           44          43          45          42          46          52          54          56
  Female                                                             54                                       52                                                      53                                51           52          47          56          54          54          45          46          44
  Atopic                                                                                                      58                                                      60                                             57          53                      50          48                      58          58
  **Mean (SD)**                                                                                                                                                                                                                                                                                      
  FEV~1~ pre-bd[d](#nt110){ref-type="table-fn"} (L)               2.6 (0.8)                                2.7 (0.8)                                              2.8 (0.8)                         2.5 (0.9)     2.6(0.9)    2.8 (0.9)   2.8 (0.8)   2.9 (0.8)   3.1(0.8)    2.6 (0.9)   2.7 (0.8)   2.7 (0.7)
  FEV~1~ post-bd (L)                                              2.7 (0.8)                                2.8 (0.8)                                              2.9 (0.8)                         2.6 (0.9)     2.7(0.9)    2.8 (0.9)   2.9 (0.9)   3.0 (0.8)   3.1(0.8)    2.7 (0.9)   2.8 (0.8)   2.8 (0.8)
  FVC pre-bd (L)                                                  3.2 (1.1)                                3.4 (1.1)                                               3.5(1.1)                         3.1 (1.2)     3.3(1.2)    3.4 (1.1)   3.3 (1.1)   3.6 (1.1)   3.8(1.1)    3.2 (1.1)   3.4 (1.0)   3.4 (0.9)
  FVC post-bd (L)                                                 3.3 (1.1)                                3.4 (1.1)                                              3.5 (1.1)                         3.1 (1.2)     3.3(1.2)    3.4 (1.1)   3.4 (1.2)   3.6 (1.1)   3.8(1.1)    3.2 (1.1)   3.4 (1.0)   3.4 (1.0)
  eNO (ppb)[e](#nt111){ref-type="table-fn"}                       9.7 (1.8)                                17.8(2.0)                                              8.9 (2.3)                         8.9 (1.9)     18.7(1.8)   9.7 (2.0)   9.2 (2.0)   16.3(1.7)   8.0(2.0)    8.9 (1.8)   17.9(1.8)   9.1 (1.8)
  **n** [f](#nt112){ref-type="table-fn"} **(% of 2006)**             86                                     76 (88)                                                70 (81)                              82         57(70)      52 (63)       85        69 (81)     62(73)        81        57 (70)     46 (57)
  **Mean (SD)**                                                                                                                                                                                                                                                                                      
  PEF am (L/min)[g](#nt113){ref-type="table-fn"}                  453 (106)                                456 (94)                                                447 (98)                          372 (78)     377 (72)    351 (83)    429(137)    420(131)    459(125)    382(110)    377(103)    379 (86)
  PEF pm (L/min)[g](#nt113){ref-type="table-fn"}                  450 (108)                                462 (90)                                                453 (97)                          377 (83)     386 (79)    355 (80)    420(136)    429(126)    460 (136)   396 (103)   378 (97)    379 (87)

Each subject contributed up to 63 days of data in the diary panel.

Participants in overlapping area of increased exposure zone and stack zone: diary panel cohort (2006 = 6(4); 2007 = 5(2); 2008 = 5(3)) contributed data to both zones.

Participants with spirometry and eNO.

bd-bronchodilator.

Geometric mean and SD.

Participants with PEF/symptom diary.

PEF recorded three times twice daily at morning and evening. Highest of three measurements used for each session.

The first two zones were defined using NO~2~ contours from Cal3qhc and Calmet/Calpuff dispersion modelling (see Supporting Information, [Appendix S1](#pone.0048921.s006){ref-type="supplementary-material"}). The zone around the eastern stack was included to address community concern about stack emissions, and the radius of 650 m was chosen to ensure a sufficient sample size. The control zone was in a nearby suburb, away from the influence of the tunnel, and not expected to experience any change in TRAP.

10.1371/journal.pone.0048921.t003

###### Symptom prevalence of the diary panel sub-cohort, by zone and year (n = 380)[a](#nt114){ref-type="table-fn"}.
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                                                                 Reduced exposure zone   Increased exposure zone[b](#nt115){ref-type="table-fn"}   Eastern stack zone[b](#nt115){ref-type="table-fn"}   Control zone                                                              
  ------------------------------------------------------------- ----------------------- --------------------------------------------------------- ---------------------------------------------------- -------------- --------- --------- ---- --------- --------- ---- --------- ---------
  **N** [c](#nt116){ref-type="table-fn"} (% of 2006)                      86                                     76 (88)                                                70 (81)                              82        57 (70)   52 (63)   85   69 (81)   62 (73)   81   57 (70)   46 (57)
  **%**                                                                                                                                                                                                                                                                           
  ***Symptom days*** [d](#nt117){ref-type="table-fn"}                                                                                                                                                                                                                             
  At least once                                                           99                                       96                                                      94                                96          93        98      95     97        94      94     91        98
  10% of days                                                             93                                       84                                                      79                                89          70        77      82     78        89      84     72        76
  \>20% of days                                                           69                                       67                                                      60                                73          53        62      62     64        66      63     60        61
  ***Day-time symptoms*** [d](#nt117){ref-type="table-fn"}                                                                                                                                                                                                                        
  At least once                                                           79                                       72                                                      70                                84          70        69      67     65        63      63     58        65
  \>10% of days                                                           52                                       43                                                      53                                63          42        48      49     46        48      41     40        43
  \>20% of days                                                           36                                       33                                                      37                                39          26        37      33     32        31      23     25        30
  ***Night-time symptoms*** [d](#nt117){ref-type="table-fn"}                                                                                                                                                                                                                      
  At least once                                                           64                                       61                                                      59                                73          44        50      66     59        65      54     42        52
  \>10% of days                                                           36                                       30                                                      27                                38          25        29      34     32        40      30     26        28
  \>20% of days                                                           19                                       13                                                      13                                21          12        15      18     22        21      15     19        17
  ***Wheeze*** [d](#nt117){ref-type="table-fn"}                                                                                                                                                                                                                                   
  At least once                                                           28                                       24                                                      20                                35          21        23      22     28        35      35     28        33
  \>10% of days                                                            9                                        7                                                      9                                 17           4        10      11      9         5      15     14         7
  \>20% of days                                                            3                                        7                                                      3                                 10           4         4      6       4         0      11      9         4
  ***Bronchodilator use*** [d](#nt117){ref-type="table-fn"}                                                                                                                                                                                                                       
  At least once                                                           12                                       16                                                      10                                21          11        12      6       7         8      12     12        13
  \>10% of days                                                            3                                        7                                                      6                                 12           7        10      2       3         2      6      11         4
  \>20% of days                                                            2                                        1                                                      1                                 5            5         4      0       0         0      5       9         4
  ***Cough*** [d](#nt117){ref-type="table-fn"}                                                                                                                                                                                                                                    
  At least once                                                           71                                       68                                                      60                                77          53        56      66     64        58      57     46        63
  \>10% of days                                                           43                                       33                                                      39                                48          32        35      40     38        45      36     32        37
  \>20% of days                                                           26                                       18                                                      23                                32          12        21      21     23        26      20     25        30
  ***Upper resp. symptoms*** [d](#nt117){ref-type="table-fn"}                                                                                                                                                                                                                     
  At least once                                                           50                                       50                                                      53                                60          44        44      48     49        53      40     44        50
  \>10% of days                                                           19                                       17                                                      29                                24          11        21      18     23        18      9      14        26
  \>20% of days                                                            5                                        8                                                      13                                12           7        10      6       9         3      5      11        15
                                                                                                                                                                                                                                                                                  
  Lower resp symptoms[e f](#nt118){ref-type="table-fn"}                   37                                       44                                                      33                                26          57        51      38     32        44      31     38        39
  Severe lower resp symp[e f](#nt118){ref-type="table-fn"}                 6                                        7                                                      8                                 12          16        13      5       7         6      9       7        12
  Upper resp. symptoms [e f](#nt118){ref-type="table-fn"}                 12                                       18                                                      18                                5           27        33      11     22        15      8      26        20
  Mouth symptoms [f](#nt119){ref-type="table-fn"}                         12                                       14                                                      22                                9           18        15      7      22        21      8      14         9

Each subject contributed up to 63 days of data in the diary study.

Participants in overlapping area of increased exposure zone and stack zone, diary panel cohort (2006 = 6(4); 2007 = 5(2); 2008 = 5(3)), contributed data to both zones. n =  subjects in overlapping area with spirometry; (n) = subjects in overlapping area taking part in peak flow and symptom diary.

Panel sub-cohort participants who took part in peak flow/symptom diary.

Symptoms recorded by diary. % represents proportion of subjects experiencing those symptoms a) at least one day during the study period; b) \>10% of days during the study period; c) \>20% of days during the study period.

Composite variables derived from variables measured in questionnaire (See [Table S1](#pone.0048921.s001){ref-type="supplementary-material"}, Supporting Information).

Attributes measured by questionnaire.

Eligibility criteria included: all residents within the zones; ages 2--75 years; being at home for ≥1 hour during rush hours (7∶00 am--9.30 am or 4.30 pm--7∶00 pm); and having sufficient English. Subjects were not told which zone they resided in. Participants were interviewed using the adult or children's version of the questionnaire.

10.1371/journal.pone.0048921.t004

###### Odds ratios for symptoms reported by questionnaire in 2007 and in 2008 relative to 2006 adjusted for change in the control zone.
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  Outcomes measured by questionnaire          2007 vs 2006                     2008 vs 2006                                                                            
  ----------------------------------------- ---------------- ------------------------------------------------ ------- ------------------------------------------------ ---------
  ***Upper respiratory symptoms***                                                                                                                                     
  Reduced exp zone                           Baseline model                   0.7 (0.5, 1.2)                    0.2                    0.8 (0.5, 1.3)                     0.3
                                                Adjusted      0.7 (0.4, 1.2)[a](#nt120){ref-type="table-fn"}    0.2    0.8 (0.5, 1.3)[a](#nt120){ref-type="table-fn"}     0.3
  Increased exp zone                         Baseline model                   2.0 (1.2, 3.6)                   0.02                    3.2 (1.7, 6.1)                   \<0.001
                                                Adjusted      1.9 (1.0, 3.3)[a](#nt120){ref-type="table-fn"}   0.04    3.0 (1.6, 5.6)[a](#nt120){ref-type="table-fn"}   \<0.001
  Stack zone                                 Baseline model                   1.8 (1.1, 3.2)                   0.03                    1.8 (1.0, 3.2)                    0.05
                                                Adjusted      1.8 (1.1, 3.1)[a](#nt120){ref-type="table-fn"}   0.03    1.7 (1.0, 3.0)[a](#nt120){ref-type="table-fn"}    0.07
  ***Lower respiratory symptoms***                                                                                                                                     
  Reduced exp zone                           Baseline model                   0.9 (0.6, 1.3)                    0.7                    0.9 (0.6, 1.4)                     0.7
                                                Adjusted      0.9 (0.6, 1.3)[b](#nt121){ref-type="table-fn"}    0.6    0.9 (0.6, 1.4)[c](#nt122){ref-type="table-fn"}     0.6
  Increased exp zone                         Baseline model                   1.5 (1.0, 2.2)                   0.07                    1.4 (0.8, 2.2)                     0.2
                                                Adjusted      1.5 (1.0, 2.2)[b](#nt121){ref-type="table-fn"}   0.08    1.4 (0.8, 2.2)[c](#nt122){ref-type="table-fn"}     0.2
  Stack zone                                 Baseline model                   1.2 (0.8, 1.7)                    0.5                    1.6 (1.0, 2.4)                    0.05
                                                Adjusted      1.2 (0.8, 1.7)[b](#nt121){ref-type="table-fn"}    0.4    1.6 (1.0, 2.5)[c](#nt122){ref-type="table-fn"}    0.04
  ***Severe lower respiratory symptoms***                                                                                                                              
  Reduced exp zone                           Baseline model                   1.1 (0.6, 2.0)                    0.9                    1.0 (0.5, 1.9)                     1.0
                                                Adjusted      1.1 (0.6, 2.0)[d](#nt123){ref-type="table-fn"}    0.9    1.0 (0.5, 2.0)[d](#nt123){ref-type="table-fn"}     0.9
  Increased exp zone                         Baseline model                   1.2 (0.6, 2.4)                    0.7                    1.0 (0.5, 2.1)                     1.0
                                                Adjusted      1.1 (0.5, 2.2)[d](#nt123){ref-type="table-fn"}    0.8    1.0 (0.5, 2.0)[d](#nt123){ref-type="table-fn"}     0.9
  Stack zone                                 Baseline model                   3.0 (1.5, 6.0)                   0.002                   1.4 (0.7, 2.8)                     0.4
                                                Adjusted      3.2 (1.6, 6.5)[d](#nt123){ref-type="table-fn"}   0.001   1.6 (0.8, 3.3)[d](#nt123){ref-type="table-fn"}     0.2
  ***Wheeze in last 3 months***                                                                                                                                        
  Reduced exp zone                           Baseline model                   0.9 (0.5, 1.5)                    0.7                    0.9 (0.5, 1.5)                     0.7
                                                Adjusted      0.9 (0.5, 1.6)[e](#nt124){ref-type="table-fn"}    0.8    0.7 (0.3, 1.2)[f](#nt125){ref-type="table-fn"}     0.2
  Increased exp zone                         Baseline model                   1.1 (0.6, 2.0)                    0.8                    1.1 (0.6, 2.0)                     0.8
                                                Adjusted      1.2 (0.6, 2.2)[e](#nt124){ref-type="table-fn"}    0.6    1.1 (0.5, 2.4)[f](#nt125){ref-type="table-fn"}     0.7
  Stack zone                                 Baseline model                   1.8 (1.0, 3.3)                   0.06                    1.8 (1.0, 3.3)                    0.06
                                                Adjusted      2.0 (1.1, 3.6)[e](#nt124){ref-type="table-fn"}   0.03    1.5 (0.7, 3.0)[f](#nt125){ref-type="table-fn"}     0.3
  ***Cough in last 3 months***                                                                                                                                         
  Reduced exp zone                           Baseline model                   0.8 (0.6, 1.1)                    0.2                    0.9 (0.6, 1.3)                     0.4
                                                Adjusted      0.8 (0.6, 1.1)[g](#nt126){ref-type="table-fn"}    0.2    0.9 (0.6, 1.3)[h](#nt127){ref-type="table-fn"}     0.5
  Increased exp zone                         Baseline model                   1.4 (0.9, 2.0)                    0.1                    1.1 (0.7, 1.8)                     0.6
                                                Adjusted      1.5 (1.0, 2.2)[g](#nt126){ref-type="table-fn"}   0.06    1.2 (0.8, 1.9)[h](#nt127){ref-type="table-fn"}     0.4
  Stack zone                                 Baseline model                   1.1 (0.8, 1.7)                    0.5                    1.2 (0.8, 1.9)                     0.3
                                                Adjusted      1.1 (0.8, 1.7)[g](#nt126){ref-type="table-fn"}    0.5    1.3 (0.8, 1.9)[h](#nt127){ref-type="table-fn"}     0.3

Adjusted for: asthma, gas cooker or oven.

Adjusted for: age, age^2^, gender, asthma, smoker, unflued gas heater.

Adjusted for: age, age^2^, asthma, smoker, unflued gas heater.

Adjusted for: age, age^2^, asthma, smoker, ETS at home.

Adjusted for: asthma, unflued gas heater.

Adjusted for: age, age^2^, asthma, unflued gas heater.

Adjusted for: age, age^2^, asthma, smoker, gas cooker or oven.

Adjusted for: age, age^2^, gender, asthma, smoker, gas cooker or oven.

A panel sub-cohort was recruited sequentially from the entire cohort to keep a nine week diary of symptoms and lung function. We originally intended recruiting only children to the sub-cohort, but, because of the scheduled opening of the tunnel and slower than expected recruitment, we decided, in late 2006, to also recruit adults. We recruited adults and children into two approximately equal strata until the sub-cohort quota was filled.

10.1371/journal.pone.0048921.t005

###### Differences in spirometry and peak flow and odds ratios for eNO, in 2007 and 2008 relative to 2006, adjusted for change in the control zone (n = 380).
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  Lung function outcomes                                                      2007 vs 2006          2008 vs 2006                                                    
  ----------------------------------------------------------------------- -------------------- ----------------------- -------------------- ----------------------- ------
  ***FEV1-pre bronchodilator (L)*** [a b](#nt128){ref-type="table-fn"}                                                                                              
  Reduced exp zone                                                           Baseline model     −0.002 (−0.06, 0.06)           1.0            −0.01 (−0.08, 0.07)    0.9
                                                                                Adjusted        −0.002 (−0.06, 0.06)           1.0           −0.001 (−0.08, 0.08)    1.0
  Increased exp zone                                                         Baseline model      −0.02 (−0.08, 0.04)           0.5            −0.07 (−0.15, 0.00)    0.06
                                                                                Adjusted         −0.02 (−0.08, 0.04)           0.5            −0.07 (−0.15, 0.01)    0.09
  Stack zone                                                                 Baseline model      0.01 (−0.05, 0.07)            0.8           −0.002 (−0.08, 0.07)    1.0
                                                                                Adjusted         0.01 (−0.04, 0.07)            0.6            0.004 (−0.07, 0.08)    0.9
  ***FEV1-post bronchodilator (L)*** [a b](#nt128){ref-type="table-fn"}                                                                                             
  Reduced exp zone                                                           Baseline model      −0.03 (−0.12, 0.05)           0.5            −0.05 (−0.15, 0.05)    0.4
                                                                                Adjusted         −0.03 (−0.12, 0.06)           0.5            −0.05 (−0.15, 0.06)    0.4
  Increased exp zone                                                         Baseline model      0.02 (−0.07, 0.10)            0.7            −0.06 (−0.17, 0.04)    0.2
                                                                                Adjusted         0.01 (−0.07, 0.10)            0.8            −0.06 (−0.17, 0.04)    0.2
  Stack zone                                                                 Baseline model      −0.08 (−0.17, 0.00)           0.06           −0.06 (−0.16, 0.05)    0.3
                                                                                Adjusted         −0.08 (−0.16, 0.01)           0.07           −0.05 (−0.16, 0.05)    0.3
  ***FEV1/FVC-pre bronchodilator*** [b c](#nt129){ref-type="table-fn"}                                                                                              
  Reduced exp zone                                                           Baseline model      0.01 (−0.01, 0.03)            0.2            0.006 (−0.01, 0.03)    0.6
                                                                                Adjusted         0.01 (−0.01, 0.03)            0.2            0.005 (−0.01, 0.02)    0.6
  Increased exp zone                                                         Baseline model      0.002 (−0.02, 0.02)           0.8           −0.002 (−0.02, 0.02)    0.8
                                                                                Adjusted         0.002 (−0.02, 0.02)           0.8           −0.003 (−0.02, 0.02)    0.8
  Stack zone                                                                 Baseline model      0.004 (−0.01, 0.02)           0.7            0.004 (−0.01, 0.02)    0.7
                                                                                Adjusted         0.004 (−0.01, 0.02)           0.7            0.005 (−0.01, 0.02)    0.6
  ***FEV1/FVC-post bronchodilator*** [b c](#nt129){ref-type="table-fn"}                                                                                             
  Reduced exp zone                                                           Baseline model      0.009 (−0.00, 0.02)           0.2            0.003 (−0.01, 0.02)    0.6
                                                                                Adjusted         0.009 (−0.00, 0.02)           0.2            0.003 (−0.01, 0.02)    0.6
  Increased exp zone                                                         Baseline model      0.00 (−0.01, 0.01)            1.0           −0.009 (−0.02, 0.00)    0.2
                                                                                Adjusted        −0.001 (−0.01, 0.01)           0.9           −0.009 (−0.02, 0.00)    0.1
  Stack zone                                                                 Baseline model      0.005 (−0.01, 0.02)           0.5            0.009 (−0.00, 0.02)    0.2
                                                                                Adjusted         0.005 (−0.01, 0.02)           0.5            0.009 (−0.00, 0.02)    0.1
  ***FVC-pre bronchodilator (L)*** [a b](#nt128){ref-type="table-fn"}                                                                                               
  Reduced exp zone                                                           Baseline model      −0.04 (−0.12, 0.05)           0.4            −0.02 (−0.12, 0.08)    0.7
                                                                                Adjusted         −0.04 (−0.12, 0.05)           0.4            −0.02 (−0.12, 0.08)    0.8
  Increased exp zone                                                         Baseline model      −0.03 (−0.11, 0.05)           0.5            −0.09 (−0.19, 0.01)    0.09
                                                                                Adjusted         −0.03 (−0.11, 0.05)           0.5            −0.08 (−0.18, 0.02)    0.1
  Stack zone                                                                 Baseline model      0.001 (−0.08, 0.08)           1.0            −0.02 (−0.11, 0.08)    0.8
                                                                                Adjusted         0.004 (−0.08, 0.08)           0.9            −0.01 (−0.11, 0.09)    0.8
  ***FVC-post bronchodilator (L)*** [a b](#nt128){ref-type="table-fn"}                                                                                              
  Reduced exp zone                                                           Baseline model      −0.05 (−0.15, 0.05)           0.4            −0.05 (−0.16, 0.07)    0.4
                                                                                Adjusted         −0.04 (−0.14, 0.06)           0.4            −0.05 (−0.16, 0.07)    0.4
  Increased exp zone                                                         Baseline model      0.01 (−0.09, 0.11)            0.8            −0.05 (−0.16, 0.06)    0.4
                                                                                Adjusted         0.01 (−0.09, 0.11)            0.8            −0.05 (−0.16, 0.07)    0.4
  Stack zone                                                                 Baseline model     −0.11 (−0.21, −0.01)           0.03           −0.09 (−0.20, 0.02)    0.1
                                                                                Adjusted        −0.10 (−0.20, −0.01)           0.04           −0.09 (−0.20, 0.02)    0.1
  ***Peak flow (L/min) morning*** [a b d](#nt128){ref-type="table-fn"}                                                                                              
  Reduced exp zone                                                           Baseline model     −4.76 (−13.63, 4.11)           0.3           −5.74 (−16.90, 5.43)    0.3
                                                                                Adjusted        −5.20 (−14.40, 4.01)           0.3           −6.62 (−18.03, 4.79)    0.3
  Increased exp zone                                                         Baseline model     −2.56 (−11.85, 6.71)           0.6           −5.93 (−17.52, 5.65)    0.3
                                                                                Adjusted        −2.52 (−12.00, 6.95)           0.6           −4.56 (−16.46, 7.34)    0.5
  Stack zone                                                                 Baseline model     −9.69 (−18.66, −0.72)          0.03           4.31 (−6.83, 15.45)    0.5
                                                                                Adjusted        −9.77 (−18.94, −0.60)          0.04           4.64 (−6.70, 15.97)    0.4
  ***Peak flow (L/min) evening*** [a b d](#nt128){ref-type="table-fn"}                                                                                              
  Reduced exp zone                                                           Baseline model     −5.32 (−14.32, 3.67)           0.3           −6.93 (−18.39, 4.53)    0.2
                                                                                Adjusted        −5.29 (−14.61, 4.02)           0.3           −7.65 (−19.35, 4.06)    0.2
  Increased exp zone                                                         Baseline model     −0.83 (−10.24, 8.58)           0.9           −3.71 (−15.59, 8.18)    0.5
                                                                                Adjusted        −0.74 (−10.34, 8.85)           0.9           −1.82 (−14.02, 10.39)   0.8
  Stack zone                                                                 Baseline model     −8.16 (−17.25, 0.94)           0.08           2.82 (−8.62, 14.25)    0.6
                                                                                Adjusted        −7.90 (−17.19, 1.38)           0.1            3.24 (−8.38, 14.86)    0.6
  ***Exhaled nitric oxide (eNO)*** [b e](#nt129){ref-type="table-fn"}      **Ratio (95% CI)**                           **Ratio (95% CI)**                          
  Reduced exp zone                                                           Baseline model       0.94 (0.75, 1.19)            0.6             0.89 (0.71, 1.12)     0.3
                                                                                Adjusted          0.93 (0.74, 1.17)            0.5             0.92 (0.73, 1.14)     0.4
  Increased exp zone                                                         Baseline model       1.05 (0.83, 1.32)            0.7             1.08 (0.86, 1.35)     0.5
                                                                                Adjusted          1.00 (0.79, 1.26)            1.0             1.09 (0.87, 1.36)     0.4
  Stack zone                                                                 Baseline model       0.90 (0.72, 1.13)            0.4             0.90 (0.73, 1.13)     0.4
                                                                                Adjusted          0.91 (0.73, 1.14)            0.4             0.93 (0.75, 1.15)     0.5

Baseline models adjusted for: age; age^2^; height; gender; gender\*age; gender\*age^2^; gender\*height.

All adjusted models additionally adjusted for: diagnosed asthma at baseline; smoking; gas cooker or oven; unflued gas heating; ETS; education and employment status.

Baseline models adjusted for: age, gender, gender\*age.

PEF recorded three times twice daily at morning and evening.

Adjusted for age and gender.

Questionnaire {#s2c}
-------------

Questionnaires collected information on respiratory symptoms and diagnoses (wheeze, cough and asthma), eye, nose and throat symptoms, and use of medications, and on potential confounders and effect modifiers including smoking, environmental tobacco smoke (ETS) exposure, and use of gas heating and gas cooking in the home. The respiratory health questions were adapted from the ISAAC [@pone.0048921-ISAAC1] and Belmont studies [@pone.0048921-Toelle1], with questions about eye, nose and throat symptoms from the M5East study [@pone.0048921-Capon1]. We asked about symptoms experienced within the preceding three months (in contrast to 12 months for ISAAC) so that the recall period for 2007 did not extend into the pre-tunnel period. Questions on mouth symptoms in adults, which we did not expect to be associated with air pollution exposure, were used to assess reporting bias. We used questionnaire responses to construct composite variables for three primary outcomes: lower respiratory tract symptoms (LRS), severe LRS (SLRS), and upper respiratory tract symptoms (URS) (see Supporting information, [Table S1](#pone.0048921.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0048921.t006

###### Odds ratios for symptoms reported in the diary panel sub-cohort in 2007 and in 2008 relative to 2006, adjusted for change in the control zone, (n = 380).
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  Symptoms measured by diary                        2007 vs 2006                  2008 vs 2006                              
  ---------------------------------- ------------------------------------------ ----------------- ------- ----------------- ---------
  ***Day symptoms***                                                                                                        
  Reduced exp zone                                 Baseline model                0.7 (0.2, 1.7)     0.4    0.6 (0.2, 1.6)      0.3
                                      Adjusted[b](#nt134){ref-type="table-fn"}   0.6 (0.2, 1.6)     0.3    0.5 (0.2, 1.4)      0.2
  Increased exp zone                               Baseline model                0.4 (0.1, 1.1)    0.06    0.4 (0.1, 1.3)      0.1
                                                      Adjusted                   0.3 (0.1, 0.9)    0.04    0.4 (0.1, 1.1)     0.09
  Stack zone                                       Baseline model                1.1 (0.4, 2.9)     0.9    0.5 (0.2, 1.4)      0.2
                                                      Adjusted                   1.1 (0.4, 2.8)     0.9    0.4 (0.2, 1.3)      0.1
  ***Night symptoms***                                                                                                      
  Reduced exp zone                                 Baseline model                1.0 (0.4, 2.7)     1.0    0.6 (0.2, 1.6)      0.3
                                                      Adjusted                   1.0 (0.4, 2.8)     1.0    0.5 (0.2, 1.4)      0.2
  Increased exp zone                               Baseline model                0.4 (0.2, 1.2)     0.1    0.5 (0.2, 1.4)      0.2
                                                      Adjusted                   0.5 (0.2, 1.3)     0.1    0.4 (0.1, 1.2)      0.1
  Stack zone                                       Baseline model                1.4 (0.5, 3.8)     0.5    1.1 (0.4, 3.0)      0.9
                                                      Adjusted                   1.5 (0.5, 4.0)     0.5    1.0 (0.4, 2.8)      1.0
  ***Symptom days***                                                                                                        
  Reduced exp zone                                 Baseline model                1.2 (0.4, 3.6)     0.7    0.6 (0.2, 2.0)      0.4
                                                      Adjusted                   1.1 (0.4, 3.4)     0.8    0.6 (0.2, 1.9)      0.4
  Increased exp zone                               Baseline model                0.5 (0.1, 1.4)     0.2    0.8 (0.3, 2.6)      0.7
                                                      Adjusted                   0.4 (0.1, 1.2)     0.1    0.6 (0.2, 2.0)      0.4
  Stack zone                                       Baseline model                2.4 (0.8, 7.1)     0.1    1.8 (0.6, 5.6)      0.3
                                                      Adjusted                   2.5 (0.8, 7.5)     0.1    1.6 (0.5, 4.9)      0.4
  ***Upper respiratory symptoms***                                                                                          
  Reduced exp zone                                 Baseline model                0.6 (0.2, 1.6)     0.3    0.5 (0.2, 1.4)      0.2
                                                      Adjusted                   0.5 (0.2, 1.5)     0.2    0.4 (0.1, 1.2)      0.1
  Increased exp zone                               Baseline model                0.2 (0.07, 0.6)   0.005   0.1 (0.04, 0.4)    0.001
                                                      Adjusted                   0.2 (0.07, 0.6)   0.005   0.1 (0.04, 0.4)   \<0.001
  Stack zone                                       Baseline model                0.8 (0.3, 2.3)     0.7    0.3 (0.1, 0.9)     0.03
                                                      Adjusted                   0.8 (0.3, 2.2)     0.6    0.3 (0.1, 0.8)     0.02
  ***Wheeze***                                                                                                              
  Reduced exp zone                                 Baseline model                1.2 (0.3, 4.0)     0.8    0.9 (0.3, 3.5)      0.9
                                                      Adjusted                   1.4 (0.4, 4.7)     0.6    1.1 (0.3, 4.0)      0.9
  Increased exp zone                               Baseline model                0.5 (0.1, 2.0)     0.3    1.2 (0.3, 4.6)      0.8
                                                      Adjusted                   0.5 (0.2, 1.9)     0.3    1.1 (0.3, 4.2)      0.9
  Stack zone                                       Baseline model                2.2 (0.6, 7.5)     0.2    2.9 (0.8, 10.5)     0.1
                                                      Adjusted                   2.6 (0.8, 8.6)     0.1    3.3 (0.9, 11.6)    0.06
  ***Cough***                                                                                                               
  Reduced exp zone                                 Baseline model                0.9 (0.3, 2.3)     0.8    0.4 (0.1, 1.1)     0.07
                                                      Adjusted                   0.8 (0.3, 2.2)     0.7    0.3 (0.1, 0.9)     0.03
  Increased exp zone                               Baseline model                0.4 (0.1, 1.1)    0.08    0.3 (0.1, 0.9)     0.03
                                                      Adjusted                   0.4 (0.1, 1.1)    0.06    0.2 (0.1, 0.7)     0.01
  Stack zone                                       Baseline model                1.5 (0.5, 4.1)     0.4    0.6 (0.2, 1.8)      0.4
                                                      Adjusted                   1.5 (0.5, 4.1)     0.4    0.5 (0.2, 1.5)      0.2

OR-odds of higher values on the ordinal scale (symptoms experienced: 0 days; 1--10% of days;10--20% of days; and 21--100% of days) compared with lower values, assuming proportional odds.

Adjusted for: age; gender; diagnosis of asthma at baseline; smoker; ETS; gas stove or oven; unflued gas heating; education and employment status.

Diary Panel Sub-cohort {#s2d}
----------------------

In panel sub-cohort participants (n = 380) we performed allergen skin prick tests to define atopic status in 2007 and measured spirometric lung function (forced expiratory volume in one second (FEV~1~) and forced vital capacity (FVC)) and exhaled nitric oxide (eNO) once each year (2006--2008) at a home visit. We calculated the ratio of FEV~1~ as a proportion of FVC (FEV~1~/FVC) as a measure of airflow obstruction. We also asked participants to record symptoms, medication use and peak expiratory flows (PEF) twice daily for nine weeks each year at the same time of year (see Supporting information, [Appendix S2](#pone.0048921.s007){ref-type="supplementary-material"}).

10.1371/journal.pone.0048921.t007

###### Mean pollutant concentrations by year and difference in pollutant concentration from post-tunnel year compared to pre-tunnel year.
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  Site & pollutant                                      Mean pollutant levels (SD)   Difference in pollutant levels[a](#nt135){ref-type="table-fn"}                          
  ---------------------------------------------------- ---------------------------- ---------------------------------------------------------------- ----------------------- ----------------------
  ***Elevated site near eastern ventilation stack***                                                                                                                         
  NO~2~ ppb                                                     16.7 (7.0)                                     15.7 (5.3)                             −2.55 (−4.43, −0.66)    −1.00 (−2.21, 0.22)
  NOx ppb                                                      30.7 (17.8)                                    27.1 (14.1)                             −6.33 (−10.97, −1.70)   −2.10 (−3.84, −0.37)
  PM~10~ *µ*g/m^3^                                              20.2 (8.1)                                     16.1 (6.8)                             −4.02 (−6.24, −1.80)    −1.74 (−3.04, −0.43)
  PM~2.5~ *µ*g/m^3^                                             6.4 (3.6)                                      5.3 (3.2)                               −1.13 (−2.38, 0.12)    −0.26 (−0.65, 0.12)
  ***Elevated site near western ventilation stack***                                                                                                                         
  NO~2~ ppb                                                     13.4 (5.6)                                     12.1 (4.5)                             −1.96 (−3.08, −0.84)    −1.07 (−1.68, −0.45)
  NOx ppb                                                      26.1 (19.9)                                    20.6 (14.6)                             −6.05 (−10.47, −1.62)   −2.79 (−4.46, −1.11)
  PM~10~ *µ*g/m^3^                                              18.7 (7.4)                                     16.2 (7.0)                             −2.39 (−4.22, −0.56)    −0.46 (−1.94, 1.03)
  PM~2.5~ *µ*g/m^3^                                             6.2 (3.5)                                      5.3 (3.3)                              −1.02 (−1.98, −0.06)    −0.19 (−0.65, 0.27)

Difference between pre-tunnel and first post-tunnel years, estimated by autoregressive analysis.

Pre-tunnel is 25 March 06--24 March 07 and first post-tunnel year is 25 March 2007--24 March 2008.

Data for only one post-tunnel year available.

Adjusted for change in air quality at the three Sydney regional sites (averaged).

Air Quality Monitoring {#s2e}
----------------------

Two elevated air quality monitoring stations located near the ventilation stacks measured oxides of nitrogen (NOx), nitric oxide (NO), NO~2~, particulate matter less than 2.5 *µ*m and less than 10 *µ*m in diameter respectively (PM~2.5~ and PM~10~) and carbon monoxide (CO). Monitoring methods were identical to those previously described for fixed site monitoring in the study area [@pone.0048921-Cowie1].

Statistical Analysis {#s2f}
--------------------

We compared the study respondents' characteristics to the local population using Australian Census 2006 data [@pone.0048921-Australian1].

Study hypotheses were tested using a regression model. Main study factors were study year, exposure zone and their interaction. We tested the hypotheses by fitting a contrast statement to this interaction term. This approach modelled changes in symptoms and lung function between pre-tunnel year (2006) and each post-tunnel year (2007 and 2008) by zone, adjusted for the change in the control zone. Coefficients for contrasts were reported as mean differences for the continuous variables, or odds ratios for binary or multinomial variables.

To adjust for autocorrelation we fitted random intercepts for subjects and households. An additional random intercept for study year was fitted for PEF data, due to repeated measures each year. Some models with both subject and household random effects did not converge, and we re-fitted the model with random intercepts for subject only.

We fitted both baseline models and models adjusted for covariates. All models, including baseline models, included adjustment for changes in the control zone. For adult questionnaire outcomes we fitted a model adjusting additionally for mouth symptoms to assess potential reporting bias. Covariates incorporated in adjusted models were specified *a priori* and included: asthma diagnosis at baseline; smoking status; ETS at home; use of gas cooking (stove or oven); use of unflued gas heaters; education; and employment status. Covariates were retained in these models if they contributed significantly (P\<0.05) to the model.

Baseline models for FEV~1~, FVC and PEF were adjusted for height, age, age^2^, gender and their interaction, and models for FEV~1~/FVC were adjusted for age and gender and their interaction, based on models used in predictive equations [@pone.0048921-Hankinson1]. Baseline models for eNO were adjusted for age and gender. The same covariates as incorporated for the questionnaire analysis were used and all covariates were retained in these models.

Continuous variables were tested using linear regression. The distribution of eNO was skewed so its values were log-transformed. Other continuous variables were analysed without transformation. Questionnaire symptoms were analysed as binary outcomes using logistic regression. For the individual daily panel symptom data, we attempted to fit a general linear mixed model incorporating random effects for subject and day with a logit link. As these models did not converge, we used summarised data for each subject, converting daily symptom data to the proportion of days each year the subject reported symptoms, classified on an ordinal scale as: no days; 1--10%; 11--20%; and 21--100% of days. These data were analysed using ordinal regression with a cumulative logit link and a multinomial error distribution. The same covariates as specified previously were incorporated and retained in the diary symptom models.

Linear regression and multinomial regression models were fitted in Proc MIXED and Proc GLIMMIX, respectively using SAS 9.2. The logistic regression with two random effects used for the questionnaire analysis was fitted in MLwiN using the Markov Chain Monte Carlo (MCMC) estimation method, as these models did not converge when using numerical methods such as adaptive quadrature.

We used an autoregressive model to test whether there was a difference in air quality at the elevated monitoring sites between 2006 and later years, adjusting for changes in regional air quality measured at three Sydney sites by the NSW Office of Environment and Heritage (OEH). Analysis was conducted in SAS 9.2 using the AUTOREG procedure.

Results {#s3}
=======

We identified 5,614 households in all study zones in 2006 ([Figure 2](#pone-0048921-g002){ref-type="fig"}). Overall household participation rate at baseline was 33%, varying from 25% in the stack zone to 38% in the control zone (see Supporting information, [Table S2](#pone.0048921.s002){ref-type="supplementary-material"}). 20% of households refused to participate, 6% were ineligible and no contact could be made with 42% of households. Survey respondents had a similar distribution of demographic characteristics to the general population in the study area [@pone.0048921-Australian1].

Of 2,978 cohort members who completed the 2006 questionnaire, 2,191 (74%) provided data in 2007 and 1,713 (58%) in 2008 ([Figure 2](#pone-0048921-g002){ref-type="fig"}). Loss to follow up was lower in the stack zone than the control zone (odds ratio (OR) 0.73, 95% CI 0.58--0.92 for 2007 and OR 0.82, 95% CI 0.67--1.01 for 2008) and higher in the reduced exposure zone than the control zone in 2008 (OR 1.28, 95% CI 1.04--1.57).

Baseline Data and Description of Study Group Over Time {#s3a}
------------------------------------------------------

Proportions of adults and females in the entire cohort did not vary substantially between zones or over the study period ([Table 1](#pone-0048921-t001){ref-type="table"}). The prevalence of reporting wheeze, cough, diagnosed and current asthma, and use of asthma medication was similar across all zones at baseline ([Table 1](#pone-0048921-t001){ref-type="table"}). The reduced exposure zone and the stack zone had more university-educated people and people in paid work, compared with the increased exposure zone and control zone. The proportion of participants using unflued gas heaters and gas cooktops/ovens increased in all zones over the study period. The prevalence of diagnosed asthma, cough, LRS, URS, and mouth symptoms increased in 2007 and 2008 in all zones.

Supporting information, [Table S3](#pone.0048921.s003){ref-type="supplementary-material"}, presents baseline data, reported in 2006, for the cohort that participated in each year of the study. Remaining members of the cohort in 2007 and in 2008 were similar in most baseline characteristics to the initial cohort, suggesting loss-to-follow-up is unlikely to have biased comparisons between years.

Of subjects asked to participate in the panel sub-cohort, 40% refused, 4% intended moving residence, and almost 6% were ineligible due to language or age constraints ([Figure 2](#pone-0048921-g002){ref-type="fig"}). The sub-cohort included more children than the entire cohort ([Table 2](#pone-0048921-t002){ref-type="table"}), and the proportion of subjects with atopy was relatively high across all zones (50--58% in 2007). Spirometric measurements were similar across all zones in all years, although values for FEV~1~ and FVC were slightly higher in subjects residing within the stack zone ([Table 2](#pone-0048921-t002){ref-type="table"}). Participants in the stack zone and the reduced exposure zone had higher PEF readings in all years than participants from the other two zones. eNO readings were higher in 2007 than in 2006 and 2008, across all zones. Over the study period, participants in the stack zone reported increased prevalence of wheeze (at least once) and slightly more symptomatic days (\>20% of days), whereas in other zones participants reported a decrease in these symptoms ([Table 3](#pone-0048921-t003){ref-type="table"}). There was some year-to-year variation in the prevalence and frequency of diary symptoms, within each zone.

Supporting information, [Table S4](#pone.0048921.s004){ref-type="supplementary-material"}, presents baseline data, reported in 2006, for the panel sub-cohort that participated in each year. Remaining participants in 2007 and 2008 were similar in most baseline characteristics to the initial cohort except that, in all zones other than the increased exposure zone, those remaining had reported substantially more cough at baseline. Also, in the increased exposure zone and the stack zone, the remaining 2008 sub-cohort had reported slightly less "current asthma" and "asthma medication use" at baseline than the initial sub-cohort and those remaining in 2007. This suggests limited potential for selection bias due to loss-to-follow up in this sub-cohort.

Questionnaire Symptom Analysis {#s3b}
------------------------------

Relative to 2006, the odds for URS in 2007 and in 2008 were significantly increased in the increased exposure zone and the stack zone, after adjusting for change in the control zone ([Table 4](#pone-0048921-t004){ref-type="table"}). The odds for LRS and SLRS were significantly increased in 2008 and 2007 respectively, in the stack zone. The odds ratios for symptoms in the reduced exposure zone were generally at or below 1.0 in 2007 and 2008, although were not statistically significant. Adjusting for significant covariates did not change the estimates substantially ([Table 4](#pone-0048921-t004){ref-type="table"}). Similarly, adjusting for mouth symptoms in the analysis of adult questionnaire responses ((model 2), made little difference to the effect estimates (model 1) (see Supporting information, [Table S5](#pone.0048921.s005){ref-type="supplementary-material"}).

Diary Analysis {#s3c}
--------------

In the panel sub-cohort, mean post-bronchodilator FVC and morning PEF were significantly reduced among stack zone participants in 2007, compared with 2006, after adjusting for change in the control zone ([Table 5](#pone-0048921-t005){ref-type="table"}). This decrease was present, although not significant, for evening PEF. There was much less evidence of a similar change between 2006 and 2008. Although there were decreases in FEV~1~ and FVC (pre-bronchodilator) in the increased exposure zone in 2008, they were not significant. There were no significant changes in lung function, airflow obstruction (FEV~1~/FVC) or eNO in the other exposure zones.

In contrast to the questionnaire findings for the entire cohort, odds for symptoms recorded by panel sub-cohort participants were generally lower in all three exposure zones for both post-tunnel years, after adjustment for the control zone ([Table 6](#pone-0048921-t006){ref-type="table"}). No significant increases in symptom prevalence were observed in any zone. Odds ratios for symptom days and wheeze in the stack zone were substantially greater than 1 but the confidence intervals (CIs) around these estimates were very broad. Adjustment for covariates did not materially alter the findings.

After adjusting for changes in regional air quality, monitors at the elevated sites near the ventilation stacks recorded significant decreases in PM~10,~ NOx and NO~2~ in 2007 compared to 2006 ([Table 7](#pone-0048921-t007){ref-type="table"}). Similarly, we previously showed using data from four additional ground level monitors that after adjusting for changes in regional air quality and meteorological conditions, PM~10,~ NOx and NO~2~ concentrations decreased in the eastern part of the study area after the tunnel opened [@pone.0048921-Cowie1].

Discussion {#s4}
==========

We did not observe consistent evidence of an improvement in respiratory health among residents living near a major road which experienced a traffic volume reduction of 50% after opening of a road tunnel. Among residents living adjacent to tunnel feeder roads there was increased reporting of upper respiratory tract symptoms in the questionnaire survey but not in the sub-cohort who recorded symptoms in a diary. The most consistently observed change was in residents living within a 650 m radius of the eastern ventilation stack. After the tunnel opened these subjects reported more upper and lower respiratory tract symptoms and had evidence of lower spirometric function, particularly lower FVC. Significant adverse effects were seen only for the first year of tunnel use (2007) and not for the second year (2008), except for questionnaire reported lower respiratory symptoms.

The strengths of this study are the cohort intervention design, in which measurements were made in the same individuals before and after commencement of operation of the tunnel, the inclusion of both subjective and objective measures of respiratory health, adjustment for coincident trends in a control site and for time-varying confounders, and testing for reporting bias.

Apart from the stack zone findings, findings from the questionnaire survey of the entire cohort and the panel sub-cohort were not consistent. This is perplexing but points to limitations of questions and diary cards that rely on self-report. Using a summary annual measure of symptoms for each subject, rather than daily symptom scores, in the sub-cohort analysis resulted in reduced statistical power, possibly contributing to inconsistency in results, but does not explain odds ratios being in the opposite direction.

Recall or other reporting bias is a potential weakness of self-reporting, which we sought to address by asking adults about mouth symptoms. The reported prevalence of mouth symptoms increased in all zones and was greatest in the increased exposure zone and the stack zone, a pattern similar for wheeze and LRS, which might be suggestive of information bias. However, when we included mouth symptoms as a covariate in the analysis, the observed effects for other symptoms were not attenuated. Hence, we conclude that the observed associations are unlikely to be explained by reporting bias.

The previous health investigation on a different tunnel stack [@pone.0048921-Capon1] did not find an association between modelled annual average NOx concentrations representing ground level exposures from stack emissions and self-reported eye, nose and throat symptoms assessed by telephone interview. That study did not assess other respiratory symptoms or include lung function measures, thus making it difficult to compare with findings from our study. A few traffic intervention studies have reported improvements in respiratory health outcomes including wheeze and peak flow [@pone.0048921-MacNeill1], hospitalisations for asthma [@pone.0048921-Lee1], emergency department presentations [@pone.0048921-Li1], eNO [@pone.0048921-Lin1], and nose and eye symptoms [@pone.0048921-Burr1], after redirection or closure of roads or implementation of traffic restrictions during major events. These health benefits were demonstrated despite somewhat modest reductions in air pollutant concentrations, aside from major reductions seen during the Beijing Olympic Games. However, other studies have not found an effect [@pone.0048921-Peel1]. For this local traffic intervention we did not see substantial benefits in health outcomes along the bypassed main road.

The most likely explanation for the lack of change in respiratory outcomes where this was expected is that the traffic intervention did not result in substantial changes in TRAP for most subjects. Although NO~2~ concentrations decreased adjacent to the bypassed main road, these changes were smaller than predicted, probably due to lower than predicted traffic volume through the tunnel [@pone.0048921-Cowie1]. Furthermore, changes in NO~2~ decreased markedly with increasing distance from the affected roads [@pone.0048921-Rose1], which is consistent with previous evidence of a rapid decay in NO~2~ concentrations with distance from major roads [@pone.0048921-Karner1], [@pone.0048921-Zhou1].

The findings of this study suggest an adverse health effect associated with living in the stack zone. This is based on lower and upper respiratory tract symptoms and wheeze recorded by questionnaire in the entire cohort, lung function analysis of panel participants, and (albeit not significantly) diary symptom analysis. These findings related primarily, but not exclusively to 2007, the first year of tunnel operation. While the confidence intervals for the diary symptom scores were wide, the outcomes are consistent with other effects reported for the stack zone. These findings are unexpected, given that neither the modelled stack emissions nor measured NO~2~, PM~10~ or PM~2.5~ at the elevated monitors, showed any evidence of increased concentration after the tunnel commenced operation.

Bias of some kind as an explanation for positive associations cannot be ruled out in observational studies, although, as previously discussed, we believe reporting bias is an unlikely explanation. While bias due to differential loss to follow-up is possible, there was no evidence that the remaining cohort had a higher prevalence of diagnosed asthma, current asthma or wheeze at baseline compared to the complete cohort or that smoking, education or work status changed appreciably (see Supporting information, [Tables S3](#pone.0048921.s003){ref-type="supplementary-material"} and [S4](#pone.0048921.s004){ref-type="supplementary-material"}). This suggests a lack of any major selective factors underlying loss to follow-up. Another possibility is that the findings are due to unmeasured confounding factors.

We considered whether the adverse effects in the stack zone could be due to exposure to tunnel portal emissions due to its location near the tunnel's eastern portal, an area with potential to experience an increase in pollutant concentrations [@pone.0048921-National1]. However, the LCT was designed not to allow for portal emissions. Furthermore, the residents in the 'increased exposure zone', also located near the tunnel portal, did not show the same pattern of adverse health effects. The observed effects in the stack zone might have been due to TRAP associated with a highway which traverses the zone, however, highway traffic decreased after 2006 [@pone.0048921-Cowie1].

Another possible explanation for the stack zone findings is an alternative pollutant source located in the industrial area near the zone. While the local government authority indicated that land zoning did not change in the industrial estate during the study timeframe [@pone.0048921-WCC1], it does not keep records of processes undertaken on individual properties. Thus we cannot rule out this possibility but also have no direct evidence for it.

The adverse findings in the stack zone are also not attributable to any measured pollutants emitted from the eastern ventilation stack, as discussed above. In addition, previous analysis of air quality data showed a decrease in NO~2~, PM~10~ or PM~2.5~ in the eastern section of the study area, over the study period [@pone.0048921-Cowie1]. Furthermore, the choice of a 650 m buffer for the stack zone was based on sample size considerations, rather than on any modelled or measured pollutant profiles.

It is possible, though, that the adverse findings are due to pollutants or size fractions other than those measured. Measurements of PM~10~ probably do not adequately reflect the particulate content of emissions in tunnels [@pone.0048921-National1] and some studies show that PM~10~ and PM~2.5~ do not represent TRAP as well as other pollutants such as NOx, NO~2~, black carbon or elemental carbon [@pone.0048921-Fischer1], [@pone.0048921-RoordaKnape1]. Smaller size PM fractions that is, PM~1~ or PM~0.1~ (ultrafine particles (UFP)) are of lower mass, are present in far greater numbers, and, due to their oxidative potential, larger surface areas and ability to attach to other compounds, are considered to pose greater toxicity risks than PM~10~ [@pone.0048921-Lodovici1]--[@pone.0048921-MazzoliRocha1]. Furthermore, elevated levels of UFP have been observed inside tunnels [@pone.0048921-Knibbs1].

The finding of adverse respiratory health effects among residents living in the eastern stack zone is unexpected and difficult to explain, and as pollutant concentrations decreased in the immediate area, we are unable to attribute the effects to the ventilation stack. However, the findings imply the need to investigate the emission profile of the stack and other pollutant sources in the area that might explain the findings. The lack of improvement in respiratory health among people living along the bypassed main road is disappointing but probably reflects the short distance from the bypassed road within which exposure reduction might result in measurable health improvement.
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